Table 3 Demographic and clinical features of the enrolled patients with macrophage activation syndrome (MAS)

Number of patients

13

Women/men

7/6

Age (years), mean ± SD

52.02 ± 19.01

 AOSD flare, number (%)

13 (100)

 Lymphoma, number (%)

0

 Infectious disease, number (%)

0

 WBC (10³/mL), mean ± SD

3.28 ± 1.36

 RBC (10³/mL), mean ± SD

3.31 ± 0.69

 HB (gr/dL), mean ± SD

9.19 ± 2.05

 PLT (10³/mL), mean ± SD

55.52 ± 46.54

 Serum Ferritin (ng/mL), mean ± SD

4362.15 ± 7569.70

 ESR (mm/hour), mean ± SD

71.23 ± 30.19

 CRP (mg/L), mean ± SD

74.76 ± 46.92

 Triglycerides (mg/dL), mean ± SD

183.12 ± 69.33

 ASAT (IU/L), mean ± SD

74.59 ± 41.89

 ALAT (IU/L), mean ± SD

129.98 ± 91.21

 High dosage steroid pulses, number (%)

13 (100)

 Immunosuppressive drugs, number (%)

7 (53.84)

 Cyclosporine A, number (%)

5 (38.46)

 Methotrexate, number (%)

2 (15.38)

 Etoposide

0

 Biologic drugs

2 (15.38)

Deaths, number (%)

10 (76.92)

Number of relapses in MAS-survivors patients, mean ± SD

2.66 ± 1.69